Epigallocatechin gallate inhibits the growth and promotes the apoptosis of bladder cancer cells
- Authors:
- Published online on: August 21, 2017 https://doi.org/10.3892/etm.2017.4981
- Pages: 3513-3518
-
Copyright: © Feng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Epigallocatechin gallate (EGCG) has been revealed to inhibit the proliferation and induce the apoptosis of several types of tumor, in addition to inhibiting DNA methyltransferase activity, leading to CpG demethylation. Tissue factor pathway inhibitor 2 (TFPI‑2) expression is downregulated in bladder cancer. The present study revealed that this downregulation was partly due to hypermethylation of the TFPI‑2 gene promoter, which was decreased by EGCG treatment. In addition, the present study demonstrated that EGCG could inhibit the viability and invasion, and induce the apoptosis, of bladder cancer T24 cells. Furthermore, western blot analysis and reverse transcription‑quantitative polymerase chain reaction analyses demonstrated that EGCG could upregulate the expression of TFPI‑2. These results suggest that EGCG inhibits the growth and induces the apoptosis of bladder cancer cells through restoring TFPI‑2 expression. Thus, EGCG is a potential therapeutic candidate for the treatment of bladder cancer.
